
Opinion|Videos|September 4, 2024
Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results
Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Do you think the results of this trial support the investigation of cretostimogene in combination with other checkpoint inhibitors?
- Can you briefly discuss other notable trials that are investigating cretostimogene for intermediate- or high-risk NMIBC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
FDA clears Revi Extend implant for urgency urinary incontinence
4
CAPItello-281 Trial Design and Efficacy Data in mHSPC
5













